NYSE · SNN
Smith & Nephew plc
$30.41+$0.29 (+0.96%)
Smith & Nephew plc’s quoted price sits in the lower half of its reported 52-week range, 18.01% below the high.
Loading market information…
NASDAQ · BVS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Bioventus Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.44% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Bioventus Inc.’s next earnings report is currently expected on Nov 2, 2026, with estimated earnings per share of $0.15. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Bioventus Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 6, 2025 |
| $0.08+33.33% vs estimate |
| $123.88M-15.07% vs estimate |
| Q4 2024 | Mar 11, 2025 | $0.15+87.5% vs estimate | $153.64M+23.41% vs estimate |
|---|
| Q3 2024 | Nov 5, 2024 | $0.060.0% vs estimate | $138.96M-4.05% vs estimate |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $18.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$30.41+$0.29 (+0.96%)
Smith & Nephew plc’s quoted price sits in the lower half of its reported 52-week range, 18.01% below the high.
$12.83+$0.59 (+4.82%)
Integra LifeSciences Holdings Corporation’s quoted price sits in the lower half of its reported 52-week range, 37.38% below the high.
$3.97+$0.02 (+0.51%)
MiMedx Group, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.19% below the high.
$10.24+$0.20 (+1.99%)
Orthofix Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.73% below the high.
$21.79+$0.24 (+1.11%)
Anika Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.76% below the high.
$0.82-$0.01 (-0.7%)
Organogenesis Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.43% below the high.
$0.92-$0.06 (-5.74%)
TELA Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.67% below the high.
$0.29+$0.00 (+1.54%)
Xtant Medical Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.43% below the high.
